Voltar
Artigo Acesso aberto Produção Nacional Revisado por pares
BIBTEX RIS

Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study

2022; Elsevier BV; Volume: 399; Issue: 10324 Linguagem: Inglês

10.1016/s0140-6736(22)00094-0

ISSN

1474-547X

Autores

Sue Ann Costa Clemens, Lily Yin Weckx, Ralf Clemens, Ana Verena Almeida Mendes, Alessandra R. Souza, Mariana B.V. Silveira, Suzete Nascimento Farias da Guarda, Maristela Miyamoto de Nobrega, Maria Isabel de Moraes Pinto, Isabela G. S. Gonzalez, Natalia Salvador, Marília Miranda Franco, Renata Navis de Avila Mendonça, Isabelle Silva Queiroz Oliveira, Bruno Solano de Freitas Souza, Mayara Fraga, Parvinder K. Aley, Sagida Bibi, Liberty Cantrell, Wanwisa Dejnirattisai, Xinxue Liu, Juthathip Mongkolsapaya, Piyada Supasa, Gavin Screaton, Teresa Lambe, Merryn Voysey, Andrew J. Pollard, Mustapha Bittaye, Danielle Woods, Sophie Davies, Holly Smith, Marta Ulaszewska, Helen Sanders, Reece Mabette, Sophie Vernon, Zara Valliji, Gracie Mead, Chitra Tejpal, Juyeon Park, Amy Beveridge, Ahmed Eldawi, Sally Felle, Mayara Fraga, Thaiane Muniz Martins, Claudia Loureiro Martins Medrado, Laiana Januse de Arruda Cordeiro Matos,

Tópico(s)

COVID-19 Clinical Research Studies

Resumo

The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has been widely used in a two-dose schedule. We assessed whether a third dose of the homologous or a different vaccine could boost immune responses.

Referência(s)